MX367657B - Moduladores del receptor p2x3 y p2x2/3 de diaminopiridina para el tratamiento de la tos aguda, sub-aguda o crónica. - Google Patents

Moduladores del receptor p2x3 y p2x2/3 de diaminopiridina para el tratamiento de la tos aguda, sub-aguda o crónica.

Info

Publication number
MX367657B
MX367657B MX2016002289A MX2016002289A MX367657B MX 367657 B MX367657 B MX 367657B MX 2016002289 A MX2016002289 A MX 2016002289A MX 2016002289 A MX2016002289 A MX 2016002289A MX 367657 B MX367657 B MX 367657B
Authority
MX
Mexico
Prior art keywords
acute
treatment
diaminopyrimidine
sub
chronic cough
Prior art date
Application number
MX2016002289A
Other languages
English (en)
Other versions
MX2016002289A (es
Inventor
P Ford Anthony
G Mccarthy Bruce
Original Assignee
Afferent Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52480919&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX367657(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Afferent Pharmaceuticals Inc filed Critical Afferent Pharmaceuticals Inc
Publication of MX2016002289A publication Critical patent/MX2016002289A/es
Publication of MX367657B publication Critical patent/MX367657B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Esta invención pertenece a compuestos de diaminopirimidina que tienen actividad como antagonistas de receptores purinérgicos de P2X, y a métodos para el tratamiento de enfermedades asociadas con receptores de P2X que comprenden administrar una cantidad efectiva de un compuesto de diaminopirimidina. Más particularmente, los métodos se proporcionan para utilizar antagonistas de P2X3 y/o P2X2/3 en el tratamiento de la tos, tos crónica, una necesidad para toser durante padecimientos y trastornos respiratorios.
MX2016002289A 2013-08-23 2014-08-22 Moduladores del receptor p2x3 y p2x2/3 de diaminopiridina para el tratamiento de la tos aguda, sub-aguda o crónica. MX367657B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361869174P 2013-08-23 2013-08-23
PCT/US2014/052389 WO2015027212A1 (en) 2013-08-23 2014-08-22 Diaminopyrimidine p2x3 and p2x 2/3 receptor modulators for treatment of acute, sub-acute or chronic cough

Publications (2)

Publication Number Publication Date
MX2016002289A MX2016002289A (es) 2016-09-06
MX367657B true MX367657B (es) 2019-08-30

Family

ID=52480919

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016002289A MX367657B (es) 2013-08-23 2014-08-22 Moduladores del receptor p2x3 y p2x2/3 de diaminopiridina para el tratamiento de la tos aguda, sub-aguda o crónica.

Country Status (20)

Country Link
US (3) US9284279B2 (es)
EP (2) EP3035932A4 (es)
JP (3) JP6546592B2 (es)
KR (1) KR102196885B1 (es)
CN (1) CN105682659B (es)
AU (1) AU2014308606B2 (es)
CA (1) CA2921395C (es)
CL (3) CL2016000400A1 (es)
CR (1) CR20160093A (es)
IL (1) IL244131B (es)
MX (1) MX367657B (es)
MY (1) MY195728A (es)
NI (1) NI201600029A (es)
NZ (1) NZ716977A (es)
PE (1) PE20160431A1 (es)
PH (1) PH12016500357A1 (es)
RU (1) RU2650118C2 (es)
SG (1) SG11201601145RA (es)
UA (1) UA118851C2 (es)
WO (1) WO2015027212A1 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX367657B (es) 2013-08-23 2019-08-30 Afferent Pharmaceuticals Inc Moduladores del receptor p2x3 y p2x2/3 de diaminopiridina para el tratamiento de la tos aguda, sub-aguda o crónica.
PL3104854T3 (pl) 2014-02-10 2020-11-30 Respivant Sciences Gmbh Stabilizatory komórek tucznych do leczenia choroby płuc
EP3653207A1 (en) 2014-02-10 2020-05-20 Respivant Sciences GmbH Mast cell stabilizers treatment for systemic disorders
WO2017011729A1 (en) 2015-07-16 2017-01-19 Patara Pharma, LLC Combination therapies for the treatment of lung diseases
EP3331522A1 (en) 2015-08-07 2018-06-13 Patara Pharma LLC Methods for the treatment of mast cell related disorders with mast cell stabilizers
US10265296B2 (en) 2015-08-07 2019-04-23 Respivant Sciences Gmbh Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
WO2017058645A1 (en) 2015-09-29 2017-04-06 Afferent Pharmaceuticals, Inc. Diaminopyrimidine p2x3 and p2x2/3 receptor modulators for use in the treatment of cough
US9907795B2 (en) * 2016-01-08 2018-03-06 Nerre Therapeutics Limited Method of treatment of chronic cough administering orvepitant in combination with other therapeutic agents
WO2017165255A1 (en) 2016-03-25 2017-09-28 Afferent Pharmaceuticals Inc. Pyrimidines and variants thereof, and uses therefor
WO2018044942A1 (en) 2016-08-31 2018-03-08 Patara Pharma, LLC Cromolyn compositions for treatment of chronic cough due to idiopathic pulmonary fibrosis
CN109803724A (zh) 2016-10-07 2019-05-24 瑞思皮万特科学有限责任公司 用于治疗肺纤维化的色甘酸组合物
EP3554504B1 (en) 2016-12-15 2022-10-26 Afferent Pharmaceuticals Inc. Substituted pyrazole-pyrimidines, variants thereof, and uses thereof
KR102557242B1 (ko) 2016-12-20 2023-07-18 애퍼런트 파마슈티컬스 인크. Ｐ2ｘ3 길항제의 결정질 염 및 다형체
US10111883B1 (en) * 2017-09-18 2018-10-30 Bellus Health Cough Inc. Selective P2X3 modulators
CN108904507A (zh) * 2018-02-11 2018-11-30 赖英杰 P2x3受体调节剂苯并咪唑化合物在制备抗呼吸疾病药物中的应用
CA3093409A1 (en) 2018-03-15 2019-09-19 Danmir Therapeutics, Llc 3",5"-dialkoxybenzoyl-3'-amino-3'-deoxyadenosine-5'-triphosphates and pharmaceutical uses thereof
CA3096505A1 (en) * 2018-04-23 2019-10-31 Merck Sharp & Dohme Corp. Novel process for synthesis of a phenoxy diaminopyrimidine compound
AU2019269049A1 (en) 2018-05-15 2020-11-26 Bayer Aktiengesellschaft 1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization
CN112384213A (zh) 2018-05-15 2021-02-19 拜耳公司 用于治疗与神经纤维敏化有关的疾病的1,3-噻唑-2-基取代的苯甲酰胺
US20200022974A1 (en) * 2018-07-23 2020-01-23 Trevi Therapeutics, Inc. Treatment of chronic cough, breathlessness and dyspnea
KR102613204B1 (ko) * 2018-10-05 2023-12-12 시오노기 앤드 컴파니, 리미티드 만성 해수 치료용 의약
EP3930722A4 (en) 2019-02-25 2022-12-28 Bellus Health Cough Inc. TREATMENT WITH P2X3 MODULATORS
AU2020265327B2 (en) * 2019-04-30 2025-09-11 Beijing Tide Pharmaceutical Co., Ltd. Method for treating cough by using diaminopyrimidine compound
KR102883943B1 (ko) 2019-04-30 2025-11-07 베이징 타이드 파마슈티컬 코퍼레이션 리미티드 디아미노피리미딘 화합물의 염, 이의 고체, 이의 제조 방법 및 이의 용도
TWI889708B (zh) 2019-09-19 2025-07-11 日商塩野義製藥股份有限公司 1，3，5-三衍生物或其溶劑合物之結晶及其製造方法
MX2022008554A (es) 2020-01-10 2022-08-10 Trevi Therapeutics Inc Metodos de administracion de nalbufina.
CN111635368B (zh) * 2020-06-12 2021-06-29 东莞市东阳光仿制药研发有限公司 一种胺化合物的制备方法
CN120019423A (zh) 2022-10-12 2025-05-16 软银集团股份有限公司 信息处理系统、信息处理装置、控制装置及程序

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2557372C (en) 2004-03-05 2013-01-08 F. Hoffmann-La Roche Ag Diaminopyrimidines as p2x3 and p2x2/3 antagonists
CA2573565A1 (en) * 2004-07-22 2006-02-02 Duska Scientific Co. Method of diagnosing, monitoring and treating pulmonary diseases
WO2007025899A1 (en) 2005-09-01 2007-03-08 F. Hoffmann-La Roche Ag Diaminopyrimidines as p2x3 and p2x2/3 modulators
MX2008002733A (es) * 2005-09-01 2008-03-26 Hoffmann La Roche Diaminopirimidinas como moduladores p2x3 y p2x2/3.
CA2620129C (en) 2005-09-01 2014-12-23 F. Hoffmann-La Roche Ag Diaminopyrimidines as p2x3 and p2x2/3 modulators
ES2374750T3 (es) * 2005-09-01 2012-02-21 F. Hoffmann-La Roche Ag Proceso de síntesis de ariloxidiaminopirimidinas.
ES2461595T3 (es) 2006-10-04 2014-05-20 F. Hoffmann-La Roche Ag Proceso para la síntesis de derivados de fenoxi-diaminopirimidina
WO2008104474A1 (en) * 2007-02-28 2008-09-04 F. Hoffmann-La Roche Ag Diaminopyrimidines
JP6124351B2 (ja) * 2012-02-09 2017-05-10 塩野義製薬株式会社 複素環および炭素環誘導体
MX367657B (es) 2013-08-23 2019-08-30 Afferent Pharmaceuticals Inc Moduladores del receptor p2x3 y p2x2/3 de diaminopiridina para el tratamiento de la tos aguda, sub-aguda o crónica.
US9222282B2 (en) * 2013-10-11 2015-12-29 Nexkey, Inc. Energy efficient multi-stable lock cylinder

Also Published As

Publication number Publication date
EP3035932A4 (en) 2017-01-04
CN105682659B (zh) 2019-12-10
PE20160431A1 (es) 2016-06-02
US20160263112A1 (en) 2016-09-15
US9724346B2 (en) 2017-08-08
IL244131A0 (en) 2016-04-21
JP7210348B2 (ja) 2023-01-23
CL2016000400A1 (es) 2017-01-20
JP2023002662A (ja) 2023-01-10
AU2014308606A1 (en) 2016-03-10
CR20160093A (es) 2016-08-26
CN105682659A (zh) 2016-06-15
NZ716977A (en) 2017-09-29
EP3035932A1 (en) 2016-06-29
CA2921395A1 (en) 2015-02-26
JP6546592B2 (ja) 2019-07-17
IL244131B (en) 2019-06-30
HK1222126A1 (zh) 2017-06-23
NI201600029A (es) 2017-09-22
KR102196885B1 (ko) 2020-12-30
AU2014308606B2 (en) 2017-08-03
RU2650118C2 (ru) 2018-04-09
MX2016002289A (es) 2016-09-06
JP2019112459A (ja) 2019-07-11
US20170326142A1 (en) 2017-11-16
JP7423725B2 (ja) 2024-01-29
CA2921395C (en) 2022-04-26
CL2018002137A1 (es) 2018-10-05
EP3865134A1 (en) 2021-08-18
KR20160052581A (ko) 2016-05-12
US10206922B2 (en) 2019-02-19
PH12016500357A1 (en) 2016-05-16
US20150057299A1 (en) 2015-02-26
RU2016105581A (ru) 2017-09-28
WO2015027212A1 (en) 2015-02-26
SG11201601145RA (en) 2016-03-30
US9284279B2 (en) 2016-03-15
UA118851C2 (uk) 2019-03-25
MY195728A (en) 2023-02-07
CL2018002138A1 (es) 2018-10-05
JP2016528301A (ja) 2016-09-15

Similar Documents

Publication Publication Date Title
PH12016500357A1 (en) Diaminopyrimidine p2x3 and p2x 2/3 receptor modulators for treatment of acute, sub-acute or chronic cough
PH12019501448A1 (en) Immunomodulator compounds and methods of use
MX390084B (es) Moduladores del receptor p2x3 y p2x2/3 de diaminopirimidina para usarse en el tratamiento de la tos.
MX2016005560A (es) Compuestos agonistas triples de glucagon-glp-1-gip.
MX384192B (es) Composiciones farmaceuticas que comprenden un antagonista de il-4r para usarse en el tratamiento del asma.
BR112014020826A2 (pt) moduladores e métodos de uso
PH12016501966B1 (en) Compounds and compositions as toll-like receptor 7 agonists
PH12017500639A1 (en) Neuroactive compounds and methods of use thereof
MY172578A (en) Oral dosing of glp-1 compounds
BR112016009889A2 (pt) ?compostos agonistas duplos gip-glp-1 e métodos?
MX371344B (es) Antagonistas de il-4r para usarse en el tratamiento o prevención de asma persistente y asma severa.
UA117032C2 (uk) Селективний інгібітор фосфатидилінозитол-3-кінази-гамма
PH12017500710A1 (en) Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists
MX2016007356A (es) Composicion para administracion oral de agentes bioactivos.
IT201600130012A1 (it) Composizione per uso nel trattamento di disturbi dell'apparato uro-genitale
PH12015502820A1 (en) Nanoparticulate formulation comprising a trpa1 antagonist
MX371343B (es) Moduladores del receptor x hepatico (lxr).
MX2016006657A (es) Antagonistas de gastrina (por ejemplo, yf476, netazepido) para el tratamiento y prevencion de osteoporosis.
BR112016019893A2 (pt) composições de glicoproteína sialilada e seus usos
NZ724799A (en) Compositions and methods for the treatment or prevention of neurodegenerative disorders
ES2586805T3 (es) Análogos de péptidos para tratar enfermedades y trastornos
ZA202002480B (en) Methods for treating or preventing asthma by administering an il-4r antagonist
HK1231767A1 (en) Methods for treating or preventing asthma by administering an il-4r antagonist
JO3621B1 (ar) مركبات وتركيبات على هيئة عوامل مساعدة لمستقبل 7 يشبه toll
MX2019009243A (es) Antagonistas il-4r para usarse en el tratamiento o previncion de asma persistente y asma severa.

Legal Events

Date Code Title Description
FG Grant or registration